Table 3 Information of patients participating in evaluation processes

Sex

Male

[46, 77]

2

Female

[43]

1

Male and female

[26,27,28,29, 31,32,33,34,35,36,37,38,39,40,41,42, 44, 45, 47,48,49,50,51,52,53,54,55,56,57,58, 60,61,62,63, 65,66,67,68,69,70,71,72,73,74,75,76, 78,79,80]

49

Participant age

<=18

[30, 67, 69, 76]

4

> 18

[26,27,28,29, 31, 33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51, 53,54,55,56,57,58,59,60, 62, 63, 65,66,67,68, 70,71,72,73, 75, 76, 78,79,80]

47

Duration of treatment

< 1 month

[26, 28, 32, 33, 35, 39, 47, 49, 51, 54, 56, 58, 60, 62,63,64, 66, 68, 72, 73, 75]

21

1–2 month

[29,30,31, 34, 36, 40, 43,44,45,46, 50, 53, 55, 57, 61, 65, 67, 69, 71, 76, 78,79,80]

23

>= 3 month

[27, 42, 48, 52, 70]

5